Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003786802 | SCV004574021 | pathogenic | Glycogen storage disease XV; Polyglucosan body myopathy type 2 | 2023-12-16 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Tyr282*) in the GYG1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 69 amino acid(s) of the GYG1 protein. This variant is present in population databases (rs768834390, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with GYG1-related conditions. This variant disrupts a region of the GYG1 protein in which other variant(s) (p.Tyr332*) have been determined to be pathogenic (PMID: 29264399). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |